Germany · Delayed Price · Currency is EUR Sartorius Aktiengesellschaft Earnings Call Transcripts
Fiscal Year 2026
-
Solid operational growth and improved profitability were achieved in H1 2026, with strong cash flow and robust demand for consumables. Guidance for full-year revenue and margin was confirmed, while tariff-related effects and delayed advanced therapy orders remain key uncertainties.
-
Sales and recurring business grew strongly in Q1 2026, with EBITDA margin resilient and cash flow up. Guidance for 2026 is confirmed, expecting 5%-9% sales growth and continued deleveraging, despite FX and geopolitical risks.
-
AGM highlighted strong 2025 financial results, strategic acquisitions, and investments in innovation and sustainability. Leadership changes and refined strategy focus on portfolio, customer experience, and operational excellence. Dividend of EUR 0.73/0.74 per share proposed.
-
Ambitious midterm targets include 8%-11% organic revenue growth and 50-75 bps annual EBITDA margin expansion, driven by innovation in single-use technologies, advanced therapies, and digitalization. U.S. and Asia are key growth regions, with operational excellence and disciplined capital allocation supporting sustainable value.
Fiscal Year 2025
-
2025 saw robust growth driven by recurring business, with sales up 7.6% in constant currency and EBITDA margin at 29.7%. Guidance for 2026 anticipates 5%-9% sales growth and margin above 30%, supported by innovation, capacity expansion, and a strong order book.
-
Sales grew 7.5% in constant currencies, driven by strong consumables demand and margin expansion, despite FX and tariff headwinds. Bioprocess Solutions led growth, while Lab Products & Services stabilized. Full-year guidance was specified, with continued investment and deleveraging on track.
-
Revenue grew 6% in constant currency, led by strong consumables demand, with EBITDA margin near 30%. BPS delivered robust growth, while LPS faced headwinds from weak capital investment. Full-year guidance is confirmed, with continued focus on deleveraging and innovation.
-
Q1 2025 delivered strong sales and margin growth, led by consumables, while equipment demand stayed soft. Guidance for 2025 is robust, with 6% sales growth and 29%-30% EBITDA margin targeted. The MatTek acquisition and regulatory shifts support innovation and future growth.
-
The AGM highlighted stable revenues, strong order growth, and continued profitability despite market volatility. Leadership transitions were announced, with a new CEO set for July 2025. Strategic investments, innovation, and sustainability remain key priorities.
Fiscal Year 2024
-
2024 results met revised guidance with robust profitability and strong free cash flow, driven by recurring consumables growth and efficiency gains. Outlook for 2025 is for moderate, profitable growth above market, with margin expansion and continued deleveraging focus.
-
Nine-month 2024 results met expectations, with stable sales, strong order intake, and robust recurring business. Efficiency gains and deleveraging progressed, while equipment demand remained soft. Full-year guidance is confirmed, with growth driven by consumables and advanced therapies.
-
H1 results met targets but sales and margins declined year-over-year amid ongoing market volatility and weak demand, especially for equipment. Guidance for 2024 was lowered to flat sales with a focus on efficiency gains, while long-term fundamentals remain positive.